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RESEARCH 
Demographics and the Cost of Pharmaceuticals in a 
Private Third-Party Prescription Program 
OBJECTIVE: To compare variance in the 
cost of pharmaceuticals attributable to 
demographic variables with variance 
explained by plan characteristics, using 
prescription claims data within various 
therapeutic categories, and to examine 
differences in average cost of pharma- 
ceuticals among demographic variables 
after controlling for covariates. 
DESIGN: Retrospective, cross-sectional 
study. 
DATA COLLECTION: Data for this study 
were obtained from 1996 prescription 
claims information for the commercial 
population administered by a Rhode 
Island-based pharmacy benefit man- 
agement (PBM) company. Six therapeu- 
tic categories with the highest expendi- 
tures were analyzed. Information on 
claims for six drug categories was 
extracted using database management 
software. Statistical analyses using mul- 
tiple regression and analysis of covari- 
ance were carried out. 
RESULTS: Plan characteristics outper- 
formed demographic variables sixteen- 
fold for all drug categories combined in 
explaining variance in cost of pharma- 
ceuticals among plan enrollees. Average 
cost of pharmaceuticals differed among 
demographic variables such as age, gen- 
der, location, and place of employment 
after controlling for average wholesale 
price and days supply. 
CONCLUSIONS: The results obtained in 
this study have practical significance in 
the determination of capitation rates 
when utilization history of prospective 
members is not available. In this situa- 
tion, managed care organizations (MCOs) 
or PBMs may have to set capitation rates 
based solely on eligibility data. Signifi- 
cant differences in average drug costs 
among the members based on place of 
employment suggest that benefit man- 
agers should consider differentiating 
capitation rates according to their 
clients' businesses. Finally, the data from 
this study indicated that commercial 
members residing in Tennessee had the 
lowest average cost of pharmaceuticals 
among all states evaluated. The fact that 
one PBM manages more than 80% of the 
TennCare prescription program along 
with a significant commercial client base 
suggests that a "spillover effect" may 
exist. 
KEYWORDS: Cost of pharmaceuticals, 
demographics, plan characteristics, uti- 
lization, confounding variables, prescrip- 
tion claims data, capitation rate, pharma- 
cy benefrt 
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by Soyal R. Momin, E. Paul Larrat, 
David P Lipson, Rita M. Marcoux, and Lisa L. Harlow 
Prescription drug prices have escalated rapidly over the 
past few decades. These increases can be explained in 
large part by therapeutic innovations, increased utiliza- 
tion related to demographics, and increased coverage under 
drug benefit programs. Prescription drugs are an essential part 
of current medical treatment technology, which is why virtual- 
ly all private insurance plans, managed care organizations 
(MCOs), and state Medicaid programs cover prescription drugs 
for their enrollees. 
The emergence of pharmacy benefit management compa- 
nies (PBMs) was a major structural change in the distribution 
of pharmaceuticals during the 1990s1 Because monitoring, 
managing, and implementing a pharmacy benefit requires a 
considerable commitment of time and resources, many MCOs 
and self-insured employers have turned to PBMs to help man- 
age all or part of their pharmacy benefit programs. PBMs pro- 
Vide a variety of services designed to influence outpatient pre- 
scription drug utilization and costs. Employers and insurers 
contract with PBMs in an effort to provide accessible and cost- 
effective benefits to their members. 
MCOs and PBMs sometimes offer risk-based capitation pay- 
ment programs as an alternative to fee-for-service (FFS) for a 
variety of population groups and benefit packages. Contracts 
based on capitation reimbursement limit the payor's financial 
risk by setting a fixed dollar amount per member per unit of 
time. The MCOs or PBMs must provide all the contracted serv- 
ices for the specified amount of money or suffer a financial loss. 
With capitation payments linked to MCO premiums and 
MCOs under pressure from employers to keep premiums as 
low as possible, MCOs are under increased financial pressure 
to reduce their costs. Capitation rates must accurately reflect 
actual drug utilization if the reimbursement is to be fair to both 
the provider and the payor. Previous research has found that 
factors affecting use of health services are nOl limited to the 
characteristics of the service but often extend to the character- 
istics of the user.2 Those who price, sell, and administer pre- 
scription drug benefit programs should be aware of the effects 
of member demographics on their prescription benefit costs. 
Amendments to HMO laws in 1981 allowed the adjustment of 
capitation rates for demographic variables of the subscribers.] 
Whether the usual underwriting factors such as age, sex, occu- 
pation, and residence are sufficient for establishing annual pre- 
miums is a matter of debate.' A study examining demographic 
variables as predictors of annual outpatient expenditures con- 
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cluded that demographic characteristics perform very poorly as 
underwriting factors.' 
Still, the extent of drug use by patients of all ages is an 
important issue. Age-specific utilization rates have proved to be 
important determinants of overall expenditures on prescription 
drugs6 Cross-sectional studies have consistently indicated that 
prescription drug use increases with age.' For example, one 
study assessing the relationship of demographics to prescription 
drug use among elderly Pennsylvanians enrolled in the 
Pharmaceutical Assistance Contract for the Elderly program 
found that prescription utilization rises with age8 In another 
study, annual drug expenditures varied significantly by age and 
sex categories.9 These qualitative differentials have been validat- 
ed in national data that show mean expenditures for women to 
be 54% greater than those for men, and children's expenditures 
only half that of adult males.lo 
Gender differentials in prescription drug use have been 
reported to persist even after controlling for disease severity, the 
nature of the medical problem (acute or chronic), age, and other 
factors considered to be medically relevant.11 Specifically, both 
age and sex appear to be strongly associated with antihyperten- 
sive, antidepressant, and histamine H2 antagonist (H,-blocker) 
drug use.12-14 
Employment is associated with a lower incidence and preva- 
lence of drug use for men, but not for women." Although 
employment has a differential effect on mens and women's drug 
use, it does not affect the extent of prescription drug use.." As 
risk factors for cardiovascular disorders, depression, and ulcers 
differ among occupational groups, further research is needed to 
determine how people in different occupations differ in their 
prescription drug use. 
In 1993, Smith found that the cost of pharmaceutical serv- 
ices was correlated with geographic region.16 However, other 
studies have found little regional variation in drug use based on 
age/gender-adjusted prescription costs." 
Interest is increasing in the assessment of ambulatory health 
care databases. Much of this interest exists among health-system 
administrators who wish to better understand their cost struc- 
tures in an attempt to control costs and improve quality of 
care.18 Also, research has shown that outpatient services are gen- 
erally more predictable than inpatient services.' 
Claims data can provide accurate information on drugs dis- 
pensed. In addition, claims data are not subject to the recall 
problems that are found with self-reported data and can provide 
a more representative picture of drug utilization than provider- 
based studies.19 Although these data are somewhat limited in 
that they often do not consistently identify the prescribing 
physician and do not have accurate diagnosis information, they 
do provide excellent population profiles of drug utilization. 
These profiles, once created, can be easily supplemented with 
additional information to improve their utility. 
Using prescription claims data, the objectives of this study 
were: (1) to compare the proportion of variation in cost of phar- 
maceuticals that could be explained by available demographic 
variables and plan characteristics within various therapeutic 
categories; and (2) to determine whether the average cost of 
pharmaceuticals differed with various demographic variables 
after controlling for appropriate covariates. 
_ Methodology 
Study Description 
Data for this study were obtained from prescnptlOn claims 
information compiled during 1996 for the commercial popula- 
tion administered by MIM Health Plans, Inc., a Rhode 
Island-based PBM. These data were collected from pharmacies 
at the point of service during the routine filling of members' 
prescriptions. Data elements conformed to National Council on 
Prescription Drug Processing standards for pharmacy claims 
adjudication. Algorithms to assure data accuracy were applied 
at the point of service and retrospectively by the PBM. All data 
were blinded as to patient name, assuring confidentiality of 
medical information. The study was approved by the University 
of Rhode Island Institutional Review Board on Human Subjects. 
Measures 
Each record in a claims file represented a prescription dispensed 
to a member. The information in the record included National 
Association of Boards of Pharmacy (NABP) pharmacy identifi- 
cation number, date of service, national drug code for the med- 
ication, Generic Product Identifier, generic name, number of 
prescriptions, quantity dispensed, amount paid by the member 
(copayment), amount reimbursed to the pharmacy provider, 
member identification number, gender, age, carrier name, 
account name, group name, and number of days supply. 
The NABP number was used to link claims files with phar- 
macy files to find the name and location of the pharmacy. The 
unique combination of carrier, account, and group representing 
a particular plan was used to determine place of the member's 
employment. Based on the National Occupational Classifica- 
tion, members were assigned to one of the following employ- 
ment categories: management, commerce, health, social sci- 
ences, lawyers and educators, art, sales and services, trade and 
transport, primary industries, manufacturing, and contractors20 
The database contained no information on the member's 
place of residence, race/ethnicity, educational level,or income, 
so measuring the effect of these demographic variables on the 
cost of pharmaceuticals was not possible. However, pharmacy 
location was used as a proxy variable for residence, because 
members are likely to present their prescriptions to pharmacies 
near their homes. 
In addition to demographic information, a file on member 
eligibility contained each member's enrollment history. Each 
member was identified by a member number and might have 
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been the original enrollee (subscriber) or a dependent. 
Questions on continuity of coverage can be answered from the 
information in this file, which maintains a temporal view of the 
member's activity within the system. Member identification 
numbers were used as a common field to link claims files with 
eligibility files to determine the member's eligibility. 
Because claims data were never structured to answer the spe- 
cific questions of this study, algorithms were designed for extract- 
ing 
.appropriate subsets of claims using database management 
software (Dbase 2.6). The Generic Product Identifier codes 
(Medispan, Inc.) were used to divide prescription drugs into 
major therapeutic categories. Claims files were indexed with 
reversed claims, marked manually, and deleted to ensure that the 
data for analysis did not include any denied or reversed claims. A 
claim reversal occurs when a pharmacist must resubmit a claim 
because of a coding error, a missing drug identification code, or 
other inaccurate information. The error is corrected by entering a 
claim identical to the first claim but with negative financial val- 
ues. The third record reflects the correct information. 
The six therapeutic categories with the highest expenditures 
during fiscal year 1996 were selected for the analysis. These 
were calcium channel blockers, angiotensin converting enzyme 
(ACE) inhibitors, lipotropics, antidepressants, H,-blockers, and 
beta-adrenergic blocking agents (beta blockers). 
Member-specific prescription data were extracted from the 
computerized records for the period January 1, 1996-Dec- 
ember 31, 1996. All members who received at least one pre- 
scription in one of these therapeutic drug categories were 
included in the analysis. The total value of claims used in the 
analysis was $1.5 million with an average of $0.15 per member 
per eligible day. For the purpose of this study, cost of pharma- 
ceuticals/drug costs was defined as the dollar expenditure for 
prescription drugs per member per eligible day. 
Outline of Statistical Analysis 
The SAS program for Windows (version 6.12) was used for all 
statistical analyses. Frequency analysis for categorical variables 
and univariate analysis for continuous variables were carried out. 
PROC UNIVARIATE and PROC PLOT were used to assess the 
assumptions of normality, linearity, and homoscedasticity. 
Because not all members were eligible during the entire fis- 
cal year 1996, in some cases utilization data did not reflect a full 
year's experience. To adjust for this, the cost of prescriptions 
was divided by eligible days, resulting in an estimate of the 
amount that members cost the plan per day. Therefore, the cost 
per member per eligible day was used as the dependent variable 
for statistical analyses. Frequency analysis revealed relatively 
few claims in states other than Tennessee. To avoid the problem 
of small numbers and unstable estimates, claims from states 
other than Tennessee were combined to form one category of 
"other states." Depending upon the drug category that was 
reviewed, the same strategy was followed for place of employ- 
ment. For example, claims for calcium channel blockers for 
members employed in management, commerce, social sciences, 
law, education, art, primary industries, and trade and transport 
businesses were combined to form one category of "other," and 
compared with those employed in manufacturing, contracting, 
health, and sales and services businesses. 
Claims for calcium channel blockers, lipotropics, ACE 
inhibitors, and beta-blockers were combined and designated as 
claims for cardiovascular drugs. Claims for antidepressants and 
H,-blockers were also combined. Finally, claims for all drug cat- 
egories were combined, resulting in nine sets of claims for 
analysis after considering each drug category individually. 
Two sets of multiple regression analyses were carried out. 
The first set using PROC REG was performed to determine the 
proportion of variation in the cost of pharmaceuticals that could 
be explained by age, gender, location, and place of employment 
for the six drug categories and their combinations. For these 
analyses, dummy variables were used for gender, location, and 
place of employment. 
The gender variable was dummy coded as male=l and 
female=O. Location was dummy coded as Tennessee=l and 
other states=O. Dummy coding for place of employment dif- 
fered for some drug categories. For example, four dummy vari- 
ables were used (Xl, X2, X3, X4) for place of employment in 
calcium channel blockers: Manufacturing (Xl=l, X2=0, X3=0, 
X4=0); Health (Xl=O, X2=1, X3=0, X4=0); Sales and Services 
(Xl=O, X2=0, X3=1, X4=0); Contractors (Xl=O, X2=0, X3=0, 
X4=l); and Other (Xl=O, X2=0, X3=0, X4=0). Interaction terms 
were added to determine whether the explained variance could 
be significantly improved by accounting for interaction effects 
between the independent variables. Variance inflation factor 
tests were used to seek out multicollinearity problems. 
The second set of multiple regression analyses was carried 
out to examine the proportion of variation in the cost of phar- 
maceuticals that could be" explained by plan characteristics. The 
independent variables included in the analyses were number of 
days eligible, number of members eligible, average wholesale 
price (AWP), out-of-pocket expense, number of days supply, 
and quantity dispensed. Variance inflation factor tests were used 
to find any problems with multicollinearity. 
To ensure a valid comparison, analyses of covariance 
(ANCOVA) were used to evaluate the differences in average cost 
of pharmaceuticals among demographic variables. ANCOVA 
allowed us to hold constant factors that might influence the cost 
of pharmaceuticals and to observe the differences only attribut- 
able to patient demographics. The last two digits of the member 
identification number facilitated the separation of claims of sub- 
scribers from their dependents. For testing our hypotheses 
about place of employment and cost of pharmaceuticals, only 
claims by subscribers were selected. Age was analyzed after 
being categorized into five groups: 1-5, 6-20, 21-40, 41-64, 
and more than 64 years old. 
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The control variables were member age, group size, AWp, 
and number of days supply Changes in the AWP that manufac- 
turers charge for each unit of product is an indicator of price 
inflation, while days supply reflects the quantity dispensed. In 
some cases we found significant interaction between variables 
of interest (grouping variables) and the covariate, indicating 
violation of the assumption of homogeneity of regression. Effect 
sizes of interactions between grouping variables and the covari- 
ate were calculated. To understand the relative differences be- 
tween groups, we also computed least square adjusted means, 
which held the covariates constant. A value of p::;0.05 was cho- 
sen as the a priori level of significance. 
_ Results 
Sample Description 
During fiscal year 1996, 29,211 subscribers representing 
64,815 enrollees were eligible (see Table 1, right). This study 
evaluated 33,131 prescription records for six drug categories. 
The mean age of enrollees was 31.5 years. Females made up 
52.8% of the eligible population and males accounted for 
47.2%. Subscribers were mainly employed in health (39.8%), 
sales and services (17.7%), and manufacturing (10.3%). Of all 
members, 58.2% were in capitated plans; the rest were in FFS 
plans. Members were mostly enrolled in a plan with an open 
formulary (79%), followed by mandatory generic substitution 
(19.6%), and closed formulary (1.4%). 
Results of Multiple Regression Models 
Table 2 (see page 399) summarizes results of the multiple 
regression using cost per member per eligible day as a depend- 
ent variable and age, gender, location, and place of employment 
as independent variables. The regression models were signifi- 
cant at the 0.001 level for all drug categories and their combi- 
nations. The explained variance in the cost of pharmaceuticals 
by therapeutic category ranged from 1.6%-13.7%. This vari- 
ance was lowest for antidepressants and highest for H2-blockers. 
Interactions among independent variables were added in the 
models to improve the explained variance. For example, inter- 
actions among gender, location, and place of employment were 
included. Addition of interaction terms did not significantly 
improve the explained variance with the exception of all drug 
categories combined. Explained variance for all drug categories 
combined in presence of the interaction terms was 9.6% com- 
pared with 3.9% without the addition of interaction terms. The 
improvement in explained variance was associated with multi- 
collinearity problems as indicated by variance-inflation factors 
and high standard errors of beta coefficients. Regression analy- 
ses were carried out excluding interaction terms to address 
problems of multicollinearity 
Age was positively associated with the cost of pharmaceuti- 
cals for all drug categories except for beta-blockers and antide- 
r.r:Á:':f.=-- Characteristics of Enrollees in a Private / Third-Party Prescription Program 
Number of 
Participants (%) 
(N= 64,815) 
Member age" 
1-5 
6-20 
21-40 
41-64 
>64 
Mean 
5,666 (88) 
13,947 (216) 
23,739 (36.8) 
18,788 (29.1) 
2,352 (3.6) 
31.5 
Member genderb 
Female 
Male 
34,145 (52.8) 
30,584 (47.2) 
(N=29,211) 
1,236 (4.2) 
3,018 (10.3) 
1,374 (4.7) 
2,043 (7.0) 
11,634 (39.8) 
2,579 (8.8) 
671 (2.3) 
5,156 (17.7) 
682 (2.3) 
818 (2.8) 
Place of Employment of Primary Cardholder 
Management 
Manufacturing 
Contractors 
Commerce 
Health 
Social sciences, lawyers, and educators 
Art 
Sales ancl services 
Trade and transport 
Primary inclustries 
Note: As of December 31, 1996. 
a323 records missing age information. 
bS6 records missing gender information. 
pressants. Males were positively associated with the cost of 
pharmaceuticals for calcium channel blockers and beta-block- 
ers and negatively associated with lipotropics and antidepres- 
sants. The relationship was not significant for ACE inhibitors 
and H2-blockers. Residence in the state of Tennessee, which 
made up the majority of our population, was negatively associ- 
ated with cost of pharmaceuticals for all drug categories. 
Cost of pharmaceuticals was positively associated with man- 
ufacturing employees compared to employees of other busi- 
nesses for calcium channel blockers, lipotropics, and H2-block- 
ers, and was negatively associated for antidepressants. The rela- 
tionship was not significant for ACE inhibitors and beta-block- 
ers. Cost of pharmaceuticals was negatively associated with 
employment in the health professions for calcium channel 
blockers, ACE inhibitors, and beta-blockers. The relationship 
was insignificant for lipotropics, H2-blockers, and antidepres- 
sants. 
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/."'.:.1:1.... Multiple Regression Model of Cost of Pharmaceuticals for Various Drug Categories (Regression / Coefficients [Standard Error] for Cost of Pharmaceuticals by Member Demographics) 
Variable Drug Category 
1 2 3 4 5 6 7 8 9 
Intercept - - - - - - - - - 
Member age 0.0813* 0.0769* 0.0855* -0.0323** 0.1288* -0.0736* 0.0660* 0.0126 0.0135** 
(0.0003) (0.0006) (0.0003) (0.0008) (0.0004) (0.0005) (0.0003) (0.0003) (00002) 
Member gender 0.0603* -0.0623* 0.0159 0.0445* 0.0104 -0.0297* 0.0073 0.0241 * 0.0128** 
(0.0085) (0.0134) (0.0089) (0.0215) (0.0124) (00170) (0.0070) (00116) (0.0062) 
Member location -0.3294* -0.3464* -0.2774* -0.2669* -0.3351* :0.0846' -0.2444* -0.1582* -0.1947* 
(0.0116) (0.0162) (0.0127) (00259) (0.0170) (0.0244) (0.0092) (0.0166) (00086) 
Place of employment 
Manufacturing/other 0.0748* 0.0409** -0.0044 -0.0113 0.0472* -0.0379* 0.0206** -0.0287* 0.0245** 
(00145) (0.0221) (0.0160) (00393) (00232) (0.0290) (0.0121) (0.0206) (0.0167) 
Health/other -0.0375** -0.0399 -0.1089' -0.2220* 0.0017 0.0273 
-0.1177* -0.0075 -0.0103 
(0.0120) (0.0182) (00127) (0.0310) (0.0182) (0.0217) (00098) (0.0155) (0.0153) 
Sales & services/other -0.0315** -0.0455** -0.1004* -0.0524** -0.0021 -0.0253** -0.0742* -0.0275* 0.0204** 
(0.0164) (00232) (00167) (0.0381) (0.0247) (0.0323) (0.0128) (0.0225) (00173) 
Contractors/other 0.0548* - - - - - - - 0.0408* 
(0.0195) - - - - - - - (0.0196) 
Commerce/other - 0.0121 - - - 0.0435* - 0.0023 0.0235* 
(0.0278) - - - (0319) - (0.0241) (00188) 
Management/other - - 0.0365** -0.0417 0.0900* - -0.0020 - 0.0218* 
- 
- (0.0193) (0.0455) (00271) - (0.0157) - (0.0189) 
N 6,763 3,462 5,783 3,63] 4,297 8,690 19,642 13,488 33,131 
F 150.87* 76.45* 93.43* 61.30* 110.47* 21.47* 236.80* 53.11* 151.46' 
R2 0.1352 0.1341 0.1017 0.1059 0.1390 0.0170 0.0778 0.0268 0.0395 
AD].R2 0.1343 0.1324 0.1006 0.1042 0.1377 0.0162 0.0775 0.0263 0.0393 
1: Calcium channel bloc/1ers. 2: Lipotropics. 3: Angiotensin-convening enzyme inhibitors. 4: Beta-bloc/1ers. 5: H,-blockers 6: Antidepressants. 
7: Combining cardiovascular drugs (1,2,3, and 4). 8: Combining H,-blockers and antidepressants (5,6). 9: Combining all six drug categories. 
*Significant at 0.001. **Significant at 0.05. 
Cost of pharmaceuticals was negatively associated with sales 
and services employment for all drug categories except H2- 
blockers, where the relationship was not significant. Cost of 
pharmaceuticals was positively associated with contracting and 
commerce employment for calcium channel blockers and anti- 
depressants, respectively. Cost of pharmaceuticals was positive- 
ly associated with management employment for ACE inhibitors 
and H2-blockers. 
Table 3 (see page 400) provides the results of multiple 
regressions using cost per member per eligible day as a depend- 
ent variable and plan characteristics as independent variables 
for six drug categories and their combinations. Regression mod- 
els were significant at the 0.001 level. Explained variance 
ranged from 34%-87%. Explained variance was lowest for beta- 
blockers and highest for antidepressants. Small variance infla- 
tion factors indicated absence of multicollinearity. 
Results of Analyses of. Covariance 
Average wholesale price and days supply were selected as 
covariates because controlling for age and number of members 
eligible did not significantly improve the model fit (R2). In 
some cases, interactions between AWP and grouping variables, 
l 
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rlf~"'~I.=-C. Multiple Regression Model of Cost of Pharmaceuticals for Various Drug Categories (Regression / Coefficients [Standard Error] for Cost of Pharmaceuticals by Plan Characteristics) 
Variable Drug Category 
1 2 3 4 5 6 7 8 9 
Intercept - - - - - I - - - - 
Days eligible 
-0.4589* -0.3722* -0.4697* -0.2053* -0.3726* -0.2547* -0.3105* -0.2670* -0.2785* 
(00000) (0.0000) (00000) (0.0001) (00000) (0.0000) (00000) (0.0000) (0.0000) 
Members eligible 0.0228* 0.0557* 0.0629* -0.0452* 0.0236** 0.0146* 0.0042* 0.0185* 0.0059 
(0.0033) (00054) (0.0036) (0.0160) (00062) (0.0040) (0.0035) (0.0045) (0.0029) 
Average wholesale price 0.6216* 0.6764* 0.3327* 0.3291 * 0.3940* 0.9571 * 0.6376* 0.7164* 0.6405* 
(0.0043) (00042) (0.0305) (0.0390) (0.0073) (0.0089) (0.0083) (0.0092) (0.0027) 
Out-or-pocket expense 0.0018 0.0493* -0.1721* 0.2076 0.1695* -0.0258* 0.0824* 0.1171* 0.1284* 
(0.0097) (0.0165) (0.0105) (0.0412) (0.0170) (0.0160) (0.0097) (0.0150) (0.0084) 
Days supply 0.1324* 0.2761 * 0.0306* 0.1210* 0.0535* -0.0143* 0.0696* -0.0116 0.0453* 
(00170) (0.0238) (0.000l) (0.0091) (0.0043) (0.0028) (0.0023) (0.0029) (0.0018) 
Quantity dispensed 0.4721 * 0.2101 * 0.6542 * 0.2673* 0.5520* 0.4293* 0.3792 * 0.4765* 0.3937* 
(00144) (0.0186) (0.0147) (0.0557) (00271) (00145) (00141) (0.0157) (0.0105) 
N 6,519 3,343 5,651 3,184 4,462 7,809 18,700 12,372 31,073 
F 3,800.21 * 1,752.17* 2,993.54* 278.68* 1,251.00* 9,361.93* 5,058.47* 15,032.43* 9,109.77* 
R2 0.7778 0.7591 0.7609 0.3448 0.6275 0.8780 0.6188 0.7094 0.6376 
AOJR2 0.7776 0.7586 0.7606 0.3435 I 0.6270 0.8779 I 0.6187 0.7093 0.6375 
1: Calcium channel blockers. 2: Lipotropics. 3: Angiotensin-converting enzyme inhibitors. 4: Beta-blockers. 5: Hz-blockers. 6: Antidepressants. 
7: Combining cardiovascular drugs (J, 2, 3, and 4). 8: Combining H,-blockers and antidepressants (5, 6). 9: Combining all six drug categories. 
*Significant at 0.00.1. ..Significant at 0.05. 
as we]] as days supply and grouping variables, were significant. 
Effect sizes of these interactions were calculated. Values of these 
effect sizes, which approached zero, allowed the use of AWP 
and days supply as covariates without violating the assumptions 
of ANCOVA. Least square means (LSMEANS) adjusted for AWP 
and days supply were examined. 
There were significant differences in average drug costs 
among age groups. Members in the 65-and-older group were 
associated with the highest average drug costs for all drug cate- 
gories except beta-blockers and antidepressants. Significant dif- 
ferences in average cost of pharmaceuticals also existed between 
males and females. Males showed higher average drug costs for 
all drug categories except for lipotropics and antidepressants. 
For these two categories, females showed significantly higher 
average drug costs (see Table 4, page 401). 
Significant differences in average cost of pharmaceuticals 
existed among members residing in Tennessee and those resid- 
ing in other states. Compared to al1 of the states together except 
Tennessee, residents of Tennessee had the lowest average drug 
costs for all drug categories (see Table 5, page 402). 
Significant differences in average drug costs existed among 
members by occupation. For the six drug categories combined, 
members employed in contracting were associated with the 
highest average drug costs and members employed in health 
care were associated with the lowest average drug costs. Members 
employed in art, trade and transport, primary industries, and 
social sciences had the highest average cost of pharmaceuticals for 
cardiovascular drugs, while those employed in health care had 
the lowest. Combining H2-blockers and antidepressants, mem- 
bers employed in art, trade and transport, primary industries, and 
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1.f:":J.~. Analysis of Covariance of Cost of Pharmaceuticals by / Member Age and Gender for Various Drug Categories 
Drug Category 
I 1 2 I 3 I 4 5 6 7 8 I 9 
Member age 
ANCOVA I 
F (p) 1,151.32 945.07 492.97 148.17 320.56 2,674.27 2,469.39 2,164.83 4,481.56 
(0.0001) (0.0001) (0.000l) (0.0001) (0.0001) (0.0001) (0.000l) (0.0001) (0.0001) 
R' 0.4584 0.6203 0.2976 0.1689 0.2845 I 0.6506 0.4286 0.4890 0.4465 
LSMEANS 
1-5 - - - - 0.1429 - - 0.1000 0.0785 
6-20 0.0901 0.1288 0.0466 0.0336 0.1737 0.0657 0.0638 0.1058 0.0809 
21-40 0.0876 0.1260 0.0647 0.0159 0.1427 0.1014 0.0624 0.0974 0.0782 
41-64 0.0932 0.1274 0.0645 0.0261 0.1521 0.0805 0.0700 0.1041 0.0821 
>64 0.1042 0.1355 0.0745 0.0219 0.2224 0.0519 0.0728 0.1391 0.0899 
Member gender 
ANCOVA 
F (p) 1,893.35 1,887.08 802.65 227.09 584.34 5,253.35 4,897.30 4,160.03 8,851.10 
(0000l) (0.000l) (0.000l) (0.000l) (00001) (0.0001) (0.0001) (0.000l) (0.000l) 
R' 0.4559 0.6205 0.2936 0.1576 0.2662 0.6473 I 0.4273 0.4796 0.4441 
LSMEANS I 
Female 0.0919 0.1335 0.0648 0.0230 0.1571 0.0867 0.0689 0.1015 0.0810 
Male 0.0973 0.1245 0.0665 0.0247 0.1612 0.0784 0.0701 0.1164 0.0848 
1: Calcium channel blockers. 2: Lipotropics. 3: Angiotensin-converting enzyme inhibitors. 4: Beta blockers. 5: H2-blockers. 6: Antidepressants. 
7: Combining cardiovascular drugs 0,2,3, and 4). 8: Combining H,-blockers and antidepressants (5,6). 9: Combining all six drug categolies. 
social sciences showed the highest average drug costs, while those 
employed in commerce showed the lowest. 
Two-way analyses of covariance were conducted using cost per 
member per eligible day as a dependent variable, with place of 
employment and gender as the independent variables. For the six 
drug categories combined, males employed in contracting demon- 
strated the highest average cost of pharmaceuticals and females 
employed in health care demonstrated the lowest. Looking at car- 
diovascular drugs as a combined category, females employed in 
art, trade and transport, primary industries, and social sciences 
were associated with the highest average drug costs, and males 
employed in health care were associated with the lowest. 
Combining antidepressants and H2-blockers, males employed 
in health care showed the highest average cost of pharmaceu- 
ticals, while males employed in manufacturing showed the 
lowest. 
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/_Ir..:.:t.:a.... Analysis of Covariance of Cost of Pharmaceuticals by Member / Location and Place of Employment for Various Drug Categories 
D C rug ategory 
I 1 I 2 3 I 4 [ 5 6 7 8 I 9 
Member location I 
ANCOVA I 
F (p) I 1,894.45 I 1,883.16 808.52 240.93 I 591.26 5,272.03 4,912.06 4,176.50 8,875.28 
(0.0001) (0.0001) (0.0001) (0.0001) (0.0001) (0.0001) (0.0001) (0.0001) (0.0001) 
R' 0.4558 0.6194 0.2947 0.1659 0.2697 0.6477 0.4278 0.4809 0.4448 
LSMEANS 
Other 0.1734 0.2111 0.1086 0.0477 0.3402 0.1559 0.1193 0.2121 0.1460 
Tennessee 
I 0.0838 0.1126 0.0599 0.0198 .1388 0.0802 0.0618 0.0960 0.0743 
Place of employment I 
ANCOVA I 
F (p) 608.03 617.01 281.24 103.04 197.29 1,675.61 1,625.96 1,366.68 2,248.52 
(0.0001) (0.0001) (0.0001) (0.0001) (0.0001) (0.0001) (0.0001) (0.0001) (0.001) 
R' I 0.4609 0.6251 0.2992 0.2125 0.2637 0.6373 0.4286 0.4734 0.4484 
LSMEANS I 
Management I - - .0.0736 0.0264 0.1904 - 0.0737 - 0.0941 
Manufacturing I 0.0944 0.1313 0.0654 0.0190 0.1923 0.0914 0.0692 0.1144 0.0834 
Health I 0.0812 0.1197 0.0604 0.0159 0.1493 0.0858 0.0590 0.1047 0.0756 
Sales and services 0.0995 0.1194 0.0621 0.0361 0.1703 0.0857 0.0730 0.1186 0.0877 
Commerce I - 0.1336 - - - 0.0884 - 0.0993 0.0861 
Contractors I 0.1250 - - - - - - - 0.1135 
Others I 0.0938 0.1342 0.0725 0.0402 0.1563 0.1226 0.0835 I 0.1338 0.0929 
J: Calcium channel blockers. 2: Lipotropics. 3: Angiotensin-converting enzyme inhibitors. 4: Beta blockers. 5: H2-blockers. 6: Antidepressants. 7: 
Combining cardiovascular drugs (1, 2, 3, and 4). 8: Combining H2-blockers and aniLdepressants (5, 6). 9: Combining all six dmg categories. 
_ Discussion 
Several limitations should be considered before discussing the 
results of this study. The major limitation relates to the com- 
prehensiveness of the data. The database includes only drug 
products covered by the drug benefit plans. Thus, nonprescrip- 
Lion drugs, drug samples, and nonformulary drugs (when paid 
for with cash by members) are typically not included. In addi- 
tion, if a prescription drug is less expensive than the member's 
copayment, the member may pay cash and a claim may not be 
recorded. Underreponing, which occurs wiLh most third-party 
Continued 0/1 page 407 
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prescription databases, may be a limitation in this study.Z! In 
addition, prescriptions filled from out-of-network pharmacies 
were not captured. 
The study may also be limited in terms of generalizability. The 
general population may behave differently from the study popu- 
lation. Therefore, careful consideration should be used before 
extrapolating these findings beyond the study population. 
Although our data are cross-sectional and do not allow causal 
inferences, several possible explanations exist for the findings of' 
the study. 
One of the objectives of the study was to examine the pro- 
portion of variation in cost of pharmaceuticals that could be 
explained by demographic variables. In effect, we wanted to 
evaluate whether demographic variables could be used to deter- 
mine capitation rates for new enrollees. Place of employment 
was selected as one of the independent variables in the regres- 
sion models. MCOs or PBMs provide prescription drug benefits 
to employees of commercial clients irrespective of members' 
occupation. As a result, place of employment becomes a more 
relevant variable to evaluate than occupation. 
In spite of the large sample size (N=33,l3l), available 
demographic variables only explained 3.9% of variance in cost 
of pharmaceuticals for all drug categories combined. A study 
that used multiple regression analysis to determine the propor- 
tion of variance in aggregated clinic, referral, and hospital costs 
found that 20% of variation in cost could be explained by sex 
and coverage type of the enrollees.) The lowest explained vari- 
ance among all therapeutic categories was for antidepressants 
0.6%). This result may be attributable in part to the availabili- 
ty of relatively new products, increased public awareness, 
acceptance of depression as a disease, physician education pro- 
grams, and mass media attention.22 
Our study demonstrated that plan characteristics accounted 
for most of the variance unexplained by demographic variables. 
These plan characteristics consisted of number of days eligible, 
number of members eJigible, AWP of drugs dispensed, out-of- 
pocket expense, number of days supply, and quantity dis- 
pensed. When taking only plan characteristics into account, the 
explained variance for antidepressants increased to 87%. These 
results strongly indicate that data on service use and cost expe- 
rience of individuals to be covered by a risk-based capitation 
payment program are much better predictors of costs of phar- 
maceuticals than simple demographics. Wouters in 1991 found 
that prior-year outpatient drug expenditures were the strongest 
predictors of future annual outpatient drug expenditures, and 
thus should be considered important information to include in 
determination of capitation rates5 
Effect of Member Demographics on Costs of Pharmaceuticals 
Age. Members over the age of 65 had the highest average 
drug costs for all drug categories except for beta-blockers and 
antidepressants. This finding is consistent with previous studies 
that show prescription drug use often increases with age.Z3.24 A 
study assessing the importance of demographics in the selection 
of antihypertensives concluded that calcium channel blockers 
were more effective in patients over 60 years of age.Z5 Nichol et 
al., in a study of factors associated with antihypertensive pre- 
scribing, found that elderly patients (over 65 years) were 78% 
more likely and patients between the ages of 40 and 65 years 
were nearly 50% more likely to receive an antihypertensive 
than those younger than 40 years.'6 
Younger members were associated with high average cost of 
pharmaceuticals for antidepressants and beta-blockers. This 
was somewhat surprising, as increasing age has been reported 
to be associated with a higher rate of depressive symptoms.27 
The results for beta-blockers may be explained in part by results 
of previous studies that show beta-blockers to be more effective 
in younger patients than elderly patients}8 
Gender. Males showed higher average drug costs than 
females for all drug categories except for lipotropics and anti- 
depressants. These results contradict the findings of a study that 
shows that females use more types of medications and use them 
to a greater extent than males do.z9 
The average cost of pharmaceuticals for Hz-blockers is con- 
sistent with results of a study examining the prescribing of 
antacids and ulcer-healing drugs in primary care in the north of 
England.14 That study found that prescribing rates of Hz-block- 
ers were higher in males than in females. The disparity between 
the sexes was attributable to males being prescribed Hz-block- 
ers for the treatment of ulcers. 
Higher average drug costs for beta-blockers may be 
explained by previous studies. Fewer data are available, but 
beta-blockers have been shown to be less effective in females 
than males.z5 Akoki et al. found that beta-blockers were among 
the few drug categories clearly prescribed more often for 
males.30 
Many studies have shown that females are more likely than 
males to receive prescriptions for antidepressants.31-3J Rosholm 
et al., in a study of outpatient utilization of antidepressants 
using a prescription database, found that women constituted a 
disproportionately large percentage of antidepressant users." 
High utilization of lipotropics among females was not found in 
the literature and therefore needs further research. 
Location. Of all the states evaluated, members residing in 
Tennessee were associated with the lowest average cost of phar- 
maceuticals for all six therapeutic categories. These results may 
be explained by location characteristics. Tennessee is well 
known for TennCare, the health-care-system reform plan 
. 
implemented on January 1, 1994. The program was developed 
with the dual objectives of controlling rapidly rising costs of the 
state's Medicaid program and extending health insurance cover- 
age to Tennesseans who did not have access to employer-spon- 
sored or other government-sponsored health insurance." More 
than a quarter of the total population of Tennessee is currently 
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enrolJed in TennCare and the program has been successful in 
controlling costs in the Medicaid program. The state claims that 
in the first 18 months, TennCare saved about $1.6 billion in 
state and federal funds based on the expected growth rate in 
conventional Medicaid expenditures35 MIM Health Plans, Inc. 
(TennCare's primary PBM) provides prescription benefit servic- 
es for about 80% of Tennessees Medicaid prescriptions. 
MIM Health Plans' strong presence in the TennCare 
Program, along with the provision of pharmacy benefits for 
commercial clients in Tennessee, may be related to a "spillover 
effect" that arises from the application of the transfer of learning 
theory to health care providers. Spillover occurs when a health 
care provider's behavior transfers from one patient population 
to another. The prescribing habits of physicians that affect the 
TennCare population may be transferred to the Tennessee com- 
mercial population. Cost consciousness of pharmacy providers 
in Tennessee and the staff at the PBM resulting from their asso- 
ciation with TennCare might have resulted in changes in their 
professional behavior. These changes might have benefited the 
commercial population administered by the PBM in Tennessee. 
The transfer of learning from the Medicaid to the non- 
Medicaid sector has been shown in the Iowa Capitation Study, 
which demonstrated spillover of generic substitution habits 
from Medicaid to non-Medicaid prescriptions. The study con- 
cluded that non-Medicaid patients benefited from pharmacists' 
cost-containment approach in the Medicaid drug program.36 
Place of employment. Members employed in art, trade and 
transport, primary industries, and social sciences had the high- 
est average drug costs for cardiovascular drugs. This high aver- 
age drug cost may be explained by high morbidity, prevalence, 
and mortality rates for cardiovascular disease among workers in 
the transportation industry, which has been known for its low 
level of physical activity, irregular work schedules, and high 
level of psychological stress.37 
Members employed in sales and services had the lowest 
average drug costs for antidepressants. This finding is contra- 
dictory to the results of a study that assessed crude prevalence 
rates for major depression and demonstrated that people 
employed in sales had high rates of depression.38 
Members employed in art, trade and transport, primary 
industries, and social sciences demonstrated the highest average 
cost of pharmaceuticals for beta-blockers. Beta-blockers are 
widely used in post-myocardial infarction (M!) patients. The 
only research that was found to support or refute these results 
was a case-referent study estimating the relative risk of MI, 
which found increased incidence of MI among males employed 
in transport work. 39 
_ Conclusion 
The results obtained in this study have practical significance in 
the determination of capitation rates when the utilization histo- 
ry of prospective members is not available. In this situation, 
MCOs or PBMs may have to set capitation rates based solely on 
eligibility data. Furthermore, if utilization data are available, the 
temptation exists to manipulate these data to influence capita- 
tion rates. In this scenario, enrolling members initially under an 
FFS arrangement is a viable option. Data collected under an 
FFS arrangement may then be used to set capitation rates. 
In addition to highlighting the importance of utilization his- 
tory in setting capitation rates for new enrollees, the study 
results have other ramifications. MCOs or PBMs contract with 
commercial clients to provide pharmacy benefits to their 
employees irrespective of occupation. Significant differences in 
utilization among the members based on place of employment 
may be a relevant finding for management of the pharmacy 
benefit. The implications are that MCOs or PBMs should con- 
sider differentiating capitation rates according to their clients' 
businesses. Finally, the unique dynamics of the Tennessee mar- 
ketplace suggest that a spillover effect may exist due to transfer 
of learning from the Medicaid to the commercial population. 
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